TABLE 2.
Antibody activity against purified recombinant BKV proteins
| Group (no. of subjects) | Antibody (no. of samples tested) | Protein | No. (%) of samples that werea:
|
Median OD at 492 nm (interquartile range) | |||
|---|---|---|---|---|---|---|---|
| Negative | Borderline positive | Positive | Strongly positive | ||||
| HD (16) | IgG (19) | LTD1 | 11 (57.9) | 5 (26.3) | 3 (15.8) | 0 | 0.0322 (0.0128-0.0688) |
| VP1 | 7 (36.8) | 4 (21.1) | 7 (36.8) | 1 (5.3) | 0.0744 (0.0320-0.1380) | ||
| Agnoprotein | 16 (84.2) | 1 (5.3) | 2 (10.5) | 0 | 0.0120 (0.0050-0.0201) | ||
| IgM (19) | LTD1 | 19 (100) | 0 | 0 | 0 | 0.0088 (0.0043-0.0131) | |
| VP1 | 19 (100) | 0 | 0 | 0 | 0.0099 (0.0026-0.0133) | ||
| Agnoprotein | 19 (100) | 0 | 0 | 0 | 0.0046 (0.0003-0.0076) | ||
| KT patient groupsb | |||||||
| A (16) | IgG (25) | LTD1 | 11 (44.0) | 7 (28.0) | 6 (24.0) | 1 (4.0) | 0.0433 (0.0238-0.1018) |
| VP1 | 7 (28.0) | 12 (48.0) | 5 (20.0) | 1 (4.0) | 0.0676 (0.0319-0.0958) | ||
| Agnoprotein | 23 (92.0) | 2 (8.0) | 0 | 0 | 0.0006 (0.0000-0.0145) | ||
| IgM (25) | LTD1 | 20 (80.0) | 3 (12.0) | 2 (8.0) | 0 | 0.0146 (0.071-0.0316) | |
| VP1 | 19 (76.0) | 4 (16.0) | 2 (8.0) | 0 | 0.0214 (0.0103-0.0284) | ||
| Agnoprotein | 23 (92.0) | 2 (8.0) | 0 | 0 | 0.0002 (0.0000-0.0044) | ||
| B (27) | IgG (83) | LTD1 | 34 (41.0) | 18 (21.7) | 14 (16.9) | 17 (20.5) | 0.0499 (0.0193-0.5721) |
| VP1 | 14 (16.9) | 14 (16.9) | 55 (66.3) | 0 | 0.1708 (0.0633-0.2854) | ||
| Agnoprotein | 78 (94.0) | 4 (4.8) | 1 (1.2) | 0 | 0.0064 (0.0000-0.0147) | ||
| IgM (83) | LTD1 | 62 (74.7) | 15 (18.1) | 6 (7.2) | 0 | 0.0156 (0.0031-0.0389) | |
| VP1 | 37 (44.6) | 17 (20.5) | 29 (34.9) | 0 | 0.0446 (0.0226-0.1556) | ||
| Agnoprotein | 79 (95.2) | 3 (3.6) | 1 (1.2) | 0 | 0.0016 (0.0000-0.0063) | ||
| C (23) | IgG (38) | LTD1 | 10 (26.3) | 6 (15.8) | 15 (39.5) | 7 (18.4) | 0.1863 (0.0425-0.7489) |
| VP1 | 8 (21.1) | 13 (34.2) | 17 (44.7) | 0 | 0.0820 (0.0488-0.2115) | ||
| Agnoprotein | 34 (89.5) | 4 (10.5) | 0 | 0 | 0.0027 (0.0000-0.0103) | ||
| IgM (38) | LTD1 | 32 (84.2) | 3 (7.9) | 3 (7.9) | 0 | 0.0107 (0.0047-0.0212) | |
| VP1 | 23 (60.5) | 6 (15.8) | 9 (23.7) | 0 | 0.0250 (0.0095-0.0805) | ||
| Agnoprotein | 38 (100.0) | 0 | 0 | 0 | 0.0020 (0.0000-0.0062) | ||
| All (38c) | IgG (146) | LTD1 | 55 (37.7) | 31 (21.2) | 35 (24.0) | 25 (17.1) | 0.0578 (0.0215-0.5187) |
| VP1 | 29 (19.9) | 39 (26.7) | 77 (52.7) | 1 (0.7) | 0.1144 (0.0549-0.2222) | ||
| Agnoprotein | 135 (92.5) | 10 (6.8) | 1 (0.7) | 0 | 0.0042 (0.0000-0.0139) | ||
| IgM (146) | LTD1 | 114 (78.1) | 21 (14.4) | 11 (7.5) | 0 | 0.0142 (0.0041-0.0309) | |
| VP1 | 79 (54.1) | 27 (18.5) | 40 (27.4) | 0 | 0.0360 (0.0132-0.1038) | ||
| Agnoprotein | 140 (95.9) | 5 (3.4) | 1 (0.7) | 0 | 0.0016 (0.0000-0.0056) | ||
| All subjects (54) | IgG (165) | LTD1 | 66 (40.0) | 36 (21.8) | 38 (23.0) | 25 (15.2) | 0.0570 (0.0185-0.3585) |
| VP1 | 36 (21.8) | 43 (26.1) | 84 (50.9) | 2 (1.2) | 0.1093 (0.0541-0.2147) | ||
| Agnoprotein | 151 (91.5) | 11 (6.7) | 3 (1.8) | 0 | 0.0058 (0.0000-0.0148) | ||
| IgM (165) | LTD1 | 133 (80.6) | 21 (12.7) | 11 (6.7) | 0 | 0.0127 (0.0041-0.0265) | |
| VP1 | 98 (59.4) | 27 (16.4) | 40 (24.2) | 0 | 0.0277 (0.0103-0.0896) | ||
| Agnoprotein | 159 (96.4) | 5 (3.0) | 1 (0.6) | 0 | 0.0018 (0.0000-0.0066) | ||
a
Antibody activity was measured as the OD at 492 nm in an enzyme-linked immunosorbent assay at a serum dilution of 1:400 and was classified as follows: negative, <0.0400; borderline positive, 0.0400 to 0.0999; positive, 0.1000 to 0.9999; and strongly positive, >0.9999.
b
A, no/low-level replication; B, high-level replication; C, past replication.
c
For some KT patients, samples were drawn before the onset of, during, and after the resolution of PVAN. Therefore, this number is smaller than the total for groups A, B, and C.